EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Funded Projects
Based on current funded research
Updated December 3, 2024
Data provided by University at Buffalo Sponsored Projects Services
| Award Principal Investigator | Award Name | Award Type | Sponsor Name | Award Start Date | Award End Date | Total Cost |
|---|---|---|---|---|---|---|
| Balthasar, Dr. Joseph | UB-Abceutics SRA | Nonfederal | Abceutics | 05-Mar-24 | 05-Mar-29 | 150,000.00 |
| Balthasar, Dr. Joseph | Center for Protein Therapeutics | Nonfederal | Multiple Sponsors | 01-Sep-17 | 31-Aug-25 | 12,624,501.70 |
| Balthasar, Dr. Joseph | Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors | Federal | National Cancer Institute | 01-Jun-20 | 31-May-25 | 1,781,807.00 |
| Balthasar, Dr. Joseph | Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization | Federal | National Cancer Institute | 01-Jun-21 | 31-May-26 | 1,791,526.00 |
| Balthasar, Dr. Joseph | Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia | Federal | National Cancer Institute | 01-Jan-23 | 31-Jan-28 | 2,115,812.00 |
| Balthasar, Dr. Joseph | Improving antibody distribution with transient antigen binding inhibition | Nonfederal | Empire Discovery Institute | 08-Dec-22 | 31-Dec-24 | 180,000.00 |
| Balu-Iyer, Dr. Sathy V. | Lipid mediated oral tolerance | Federal | National Institute of Allergy & Infectious Disease | 16-Jun-22 | 31-May-27 | 2,327,530.00 |
| Balu-Iyer, Dr. Sathy V. | Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A | Federal | National Heart Lung and Blood Institute | 27-Mar-23 | 28-Feb-25 | 1,121,169.00 |
| Balu-Iyer, Dr. Sathy V. | Oral administration of Tolerance-Inducing Lyso-Phosphatidyl Serine (TIPS) nanoparticles formulated with insulin to treat T1D in NOD mice | Nonfederal | Empire Discovery Institute | 12-Jun-23 | 31-Dec-24 | 98,793.00 |
| Bednarczyk, Dr. Edward M. | Overdose Data to Action State - Best Practices in Care for People Experiencing Houselessness and SUD | Federal Flow Through | Health Research Inc. | 01-Jan-24 | 31-Dec-24 | 45,000.00 |
| Bednarczyk, Dr. Edward M. | C19: Chronic Disease Medication Utilization and the Novel Coronavirus Disease 2019 (COVID-19) Infection | Nonfederal | American College of Clinical Pharmacy | 01-Jan-21 | 31-Dec-24 | 600.00 |
| Bies, Dr. Robert R. | Long Acting Film Technology for Contraception and HIV Prevention (LATCH) | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Feb-21 | 31-Jan-25 | 269,856.00 |
| Bies, Dr. Robert R. | Evaluation of safety and pharmacokinetics of naltrexone implant | Federal Flow Through | Research Foundation of Mental Hygiene | 01-Mar-21 | 28-Feb-25 | 217,842.00 |
| Bies, Dr. Robert R. | The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC) | Federal Flow Through | Trustees of Indiana University | 10-Sep-21 | 31-Jul-26 | 1,865,877.00 |
| Bies, Dr. Robert R. | Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence, MATRIX | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Dec-21 | 31-Dec-26 | 1,413,208.00 |
| Bies, Dr. Robert R | Reproductive Tract PBPK & Exposure Modeling | Nonfederal | Magee-Womens Research Institute and Foundation | 07-Nov-22 | 31-Mar-25 | 189,280.00 |
| Bies, Dr. Robert R | Application of PBPK model of the Female Reproductive Tract (FRT) | Nonfederal | Bill and Melinda Gates Foundation | 03-Oct-23 | 28-Feb-25 | 66,319.00 |
| Chen, Dr. Liang | SBIR: Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol | Federal Flow Through | PZA Innovation Limited Liability Company | 02-Jan-24 | 31-Mar-25 | 224,960.00 |
| Cieri-Hutcherson, Dr. Nicole E | Motivators and barriers to precepting introductory and advanced pharmacy practice experiential rotations | Nonfederal | American College of Clinical Pharmacy | 15-Jun-24 | 14-Jun-25 | 1,000.00 |
| Das, Dr. Bhaskar | Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma | Federal Flow Through | University of California at Irvine | 01-Jun-24 | 30-May-25 | 251,290.00 |
| Das, Dr. Bhaskar | Blocking Pathologic Crosstalk Between Podocytes and Endothelial Cells in FSGS | Federal | US Army Medical Research Acquisition Activity | 01-May-24 | 30-Apr-28 | 1,232,000.00 |
| Gallo, Dr. James | Cell State Network-Directed Therapy | Federal Flow Through | Clemson University | 20-Sep-24 | 28-Feb-25 | 122,500.00 |
| Gallo, Dr. James | Targeting trained immunity in transplantation - Core B | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 01-Jun-23 | 31-Mar-28 | 230,216.00 |
| Jacobs, Dr. David Matthew | Integrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPD | Federal | National Heart Lung and Blood Institute | 01-Apr-21 | 31-Mar-26 | 962,055.00 |
| Jusko, Dr. William J. | Mechanistic Pharmacokinetics and Pharmacodynamics | Federal | National Institute of General Medical Sciences | 01-May-19 | 30-Apr-25 | 2,891,677.00 |
| Jusko, Dr. William J. | Training Program in Pharmacokinetics and Pharmacodynamics | Nonfederal | GlaxoSmithKline | 03-Feb-21 | 20-Aug-25 | 512,400.00 |
| Lao, Dr. Yeh-Hsing Sima | Nanoformulated CRISPR Ribonucleoproteins for Ultrasound-Facilitated Brain Gene Editing | Federal | National Inst of Neurological Disorders & Stroke | 01-Jul-23 | 30-Jun-25 | 442,000.00 |
| Ma, Dr. Qing | Doravirine Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals | Nonfederal | Merck Sharp and Dohme Limited Liability Corporation | 04-Jun-19 | 30-May-25 | 242,646.38 |
| Ma, Dr. Qing | Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV | Federal | National Institute on Aging | 01-May-20 | 28-Feb-25 | 4,006,139.00 |
| Ma, Dr. Qing | An Open-label Study Evaluating Pharmacokinetics, Efficacy, Safety, and Tolerability of CABENUVA IM Administered Monthly and Every 2 months in Virologically Suppressed HIV-Infected Adults having Severe Renal Impairment With or Without Hemodi | Nonfederal | Alleghany Singer Research Institute | 28-Feb-24 | 30-Sep-26 | 18,685.00 |
| Mager, Dr. Donald E. | Novel Synthetic Lethality Strategy for TP53 Mutant Colorectal Cancer | Federal Flow Through | Health Research Inc. | 10-Aug-23 | 31-Jul-25 | 63,555.00 |
| Mager, Dr. Donald E. | Immunologic and Neurodevelopmental Consequences of Neonatal Anemia and Thrombocytopenia and their Treatments | Federal Flow Through | Childrens Hospital of Boston | 01-Sep-18 | 31-Dec-24 | 825,510.00 |
| Mager, Dr. Donald E. | Optimizing GVHD Prevention with Systems Pharmacology Models | Federal Flow Through | Beckman Research Institute of the City of Hope | 01-Jun-19 | 31-May-25 | 646,324.00 |
| Morse, Dr. Gene | University of Rochester HIV/AIDS Clinical Trial Unit - AWD00003932 | Federal Flow Through | University of Rochester | 01-Dec-20 | 30-Nov-27 | 156,456.00 |
| Morse, Dr. Gene | HIV Clinical Pharmacology & Therapeutics Research Training Program | Federal | Fogarty International Center | 01-Mar-22 | 31-Jan-27 | 1,507,744.94 |
| Morse, Dr. Gene | Clinical Pharmacology Quality Assurance (CPQA) | Federal | National Institute of Allergy & Infectious Disease | 30-May-22 | 29-May-29 | 14,561,135.00 |
| Morse, Dr. Gene | CENTER FOR INTEGRATED GLOBAL BIOMEDICAL SCIENCES | Nonfederal | Abbott Laboratories | 23-Nov-22 | 31-Mar-25 | 174,900.00 |
| Morse, Dr. Gene | Global Infectious Diseases Research Training Program | Federal | Fogarty International Center | 01-Mar-23 | 31-Dec-27 | 1,833,196.00 |
| Prescott, Dr. Gina | Affordable Care Act: Public Health Training Centers Program | Federal Flow Through | D'Youville University | 01-Jun-2023 | 14-Sep-25 | 150,000.00 |
| Prescott, Dr. Gina | Hypertension Cascade of Care in Marginalized Populations | Nonfederal | NYS Chapter of American College of Clinical Pharmacy | 01-Jun-23 | 28-Feb-25 | 3,000.00 |
| Qu, Dr. Jun | Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications | Federal | Pacific Northwest Laboratory | 12-Mar-24 | 30-Jun-27 | 819,967.00 |
| Qu, Dr. Jun | UB CAT: Assessing an Alzheimer's Peptide Vaccine | Nonfederal | POP Biotechnologies Incorporated | 01-Jul-2024 | 30-Jun-25 | 40,034.96 |
| Qu, Dr. Jun | Identifying Chemo-Neoepitopes for the Chemo-Immunotherapy Against Triple-Negative Breast Cancer | Federal Flow Through | Health Research Inc | 01-Jun-2024 | 31-May-25 | 15,902.00 |
| Qu, Dr. Jun | Quantitation of CLDN in tissues | Nonfederal | Boehringer Ingelheim Pharmaceutical | 07-Aug-24 | 06-Aug-26 | 300,000.00 |
| Qu, Dr. Jun | Regulation of and Target Recognition by Protein Arginine Methyltransferase 1 (PRMT1) | Federal Flow Through | Utah State University | 01-Sep-24 | 30-Apr-26 | 32,226.00 |
| Qu, Dr. Jun | Membrane protein analysis and MASP tissue mapping | Nonfederal | Boehringer Ingelheim Pharmaceutical | 07-Aug-2024 | 06-Aug-26 | 300,000.00 |
| Qu, Dr. Jun | Extracellular Vesicle treatment and age-related neuropathology in non-human primates | Federal Flow Through | Trustees of Boston University | 15-Sep-20 | 30-Apr-25 | 188,473.00 |
| Qu, Dr. Jun | Role of Type 2 Immune Response in Pancreatic Cancer Tumorgenisis | Federal Flow Through | Health Research Inc | 15-Jul-21 | 30-Jun-25 | 39,175.00 |
| Qu, Dr. Jun | Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression | Federal Flow Through | Health Research Inc. | 05-Aug-22 | 31-Jul-25 | 22,080.00 |
| Qu, Dr. Jun | Mitochondrial Defects in the Retinal Pigment Epithelium and the CFH Risk Allele for Age-related Macular Degeneration | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 30-Jun-26 | 254,607.00 |
| Qu, Dr. Jun | Deciphering the Mechanisms Associated with High-risk AMD genotypes for ARMS2/HTRA1 and Complement Factor H | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 31-Aug-25 | 191,140.00 |
| Qu, Dr. Jun | Mechanisms underlying extracellular vesicle mediated changes in inflammation, neural circuitry and plasticity following cortical injury in aged monkeys | Federal Flow Through | Trustees of Boston University | 15-Jul-22 | 30-Jun-27 | 283,312.00 |
| Ramanathan, Dr. Murali | Characterization of PK-PD and Model-Informed Drug Development | Nonfederal | Bill and Melinda Gates Foundation | 14-Oct-24 | 31-Oct-25 | 273,304.00 |
| Ramanathan, Dr. Murali | The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression | Federal | US Army Medical Research Acquisition Activity | 01-Jul-20 | 30-Jun-25 | 957,000.00 |
| Shah, Dr. Dhavalkumar | Training program in pharmacokinetics and pharmacodynamics for a visiting scientist from Japan Tobacco, Inc. | Nonfederal | Japan Tobacco Incorporated | 26-Aug-2024 | 25-Aug-25 | 80,500.00 |
| Shah, Dr. Dhavalkumar | Development of organ-specific quantitative systems toxicology models for antibody-drug conjugates | Nonfederal | AstraZeneca Pharmaceuticals LP | 01-Apr-22 | 09-Oct-25 | 465,771.00 |
| Shah, Dr. Dhavalkumar | Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier | Federal Flow Through | University of Alabama | 15-Sep-23 | 30-Jun-27 | 321,323.00 |
| Smith, Dr. Nicholas M | Pharmacokinetics and Pharmacodynamics of Mechanistically Aware Phage Cocktails | Federal | National Institute of Allergy & Infectious Disease | 01-Jul-24 | 31-Jul-29 | 3,647,260.00 |
| Sprowl, Dr. Jason Arthur | Regulation of hepatic uptake transporters by tyrosine kinases | Federal | National Institute of General Medical Sciences | 15-Sep-21 | 31-Aug-26 | 2,321,588.00 |
| Sprowl, Dr. Jason Arthur | Role of MCT6 in mediating cisplatin-induced ototoxicity | Federal | National Inst on Deafness & Other Comm Disorders | 01-Apr-23 | 31-Mar-25 | 432,182.00 |
| Sprowl, Dr. Jason Arthur | CAREER: Tyrosine Phosphorylation and Kinase Activity as a Regulator of Sodium-Glucose Transporters | Federal | National Science Foundation | 01-Mar-24 | 28-Feb-29 | 746,886.00 |
| Straubinger, Dr. Robert M. | Fellowship for Jonathan Perri: Nanoparticle-Based Approaches to Generate Integrated Immune Responses in Immune Deficient Solid Tumors | Nonfederal | American Foundation Pharmaceutical Education | 01-Sep-24 | 31-Aug-25 | 10,000.00 |
| Tornatore, Dr. Kathleen M. | Age and Race Influences on Immunosuppression after Renal Transplant | Federal | National Institute on Aging | 15-Aug-18 | 30-Jun-25 | 3,507,814.00 |
| Tsuji, Dr. Brian T. | Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | Federal | National Institute of Allergy & Infectious Disease | 20-Dec-19 | 30-Nov-25 | 3,920,362.00 |
| Tsuji, Dr. Brian T. | Exploitation of multiple heteroresistance for effective antibiotic combination therapy | Federal Flow Through | Emory University | 01-Jul-20 | 30-Jul-25 | 405,663.00 |
| Tsuji, Dr. Brian T. | Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa | Federal | National Institute of Allergy & Infectious Disease | 24-May-22 | 30-Apr-27 | 3,850,992.00 |
| Woo, Dr. Sukyung | Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition | Federal | National Cancer Institute | 01-Dec-2021 | 30-Nov-26 | 1,613,192.00 |
| Woo, Dr. Sukyung | Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold | Federal Flow Through | Board of Regents of the University of Oklahoma | 01-Jul-22 | 30-Jun-27 | 408,175.00 |
| Woo, Dr. Sukyung | Route 66 Endometrial Cancer SPORE | Federal Flow Through | Washington University | 23-Aug-23 | 31-Jul-28 | 235,301.00 |
| You, Dr. Young Jae | Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers | Federal | National Cancer Institute | 13-Jul-22 | 30-Jun-27 | 2,080,525.00 |
| You, Dr. Young Jae | Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation | Federal | National Institute of General Medical Sciences | 01-Aug-23 | 31-Jul-27 | 1,372,031.00 |
| Zhao, Dr. Yanan | Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections | Federal | National Institute of Allergy & Infectious Disease | 02-Jul-24 | 30-Jun-29 | 3,898,070.00 |